{
    "data": [
        {
            "id": "643d41e757b1c7a315000037_0001",
            "question": "What is the first indication for lurasidone?",
            "type": "list",
            "context": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia"
        },
        {
            "id": "643d41e757b1c7a315000037_0002",
            "question": "What is the first indication for lurasidone?",
            "type": "list",
            "context": "he Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome:"
        },
        {
            "id": "643d41e757b1c7a315000037_0003",
            "question": "What is the first indication for lurasidone?",
            "type": "list",
            "context": "This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt\u00ae), asenapine (Saphris\u00ae), and lurasidone (Latuda\u00ae), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, "
        },
        {
            "id": "64403ab057b1c7a31500004d_0001",
            "question": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?",
            "type": "factoid",
            "context": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression."
        },
        {
            "id": "64179139690f196b5100002f_0001",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Whole-exome sequencing was utilized to detect disease-causing variants in 40 multiplex ligation-dependent probe amplification-negative DMD patients. "
        },
        {
            "id": "64179139690f196b5100002f_0002",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Whole exome sequencing analysis revealed that nonsense variant was the most common type in our study (23/36 of the cases)."
        },
        {
            "id": "64179139690f196b5100002f_0003",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": ". The present study has demonstrated the importance of performing Whole exome sequencing to detect disease-causing point mutations in multiplex ligation-dependent probe amplification-negative DMD patients and to identify carrier females."
        },
        {
            "id": "64179139690f196b5100002f_0004",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Whole exome sequencing (Whole exome sequencing) and multiple ligation-dependent probe amplification (multiplex ligation-dependent probe amplification) were used to detect potential deletions in the STS and DMD genes."
        },
        {
            "id": "64179139690f196b5100002f_0005",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "The newborns with retest positive result were recalled again for serum creatine kinase (creatine kinase) and multiplex ligation-dependent probe amplification (multiplex ligation-dependent probe amplification) test."
        },
        {
            "id": "64179139690f196b5100002f_0006",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Whole exon sequencing was performed when multiplex ligation-dependent probe amplification test was negative."
        },
        {
            "id": "64179139690f196b5100002f_0007",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": " In this study we aimed to determine the mutational spectrum of multiplex ligation-dependent probe amplification (multiplex ligation-dependent probe amplification)-negative muscular dystrophy patients in Pakistan using whole-exome sequencing. "
        },
        {
            "id": "64179139690f196b5100002f_0008",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Whole-exome sequencing identified a nonsense variant in Pakistani muscular dystrophy patients, which is amenable to treatment by Ataluren "
        },
        {
            "id": "64179139690f196b5100002f_0009",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": " We used the combination of multiplex ligation-dependent probe amplification (multiplex ligation-dependent probe amplification) and sequencing analysis of the DMD gene. "
        },
        {
            "id": "64179139690f196b5100002f_0010",
            "question": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
            "type": "list",
            "context": "We performed DNA tests in 152 patients, checking first exon deletion/duplication by multiplex ligation-dependent probe amplification, and subsequently, if negative, samples were sequenced to detect point mutations."
        },
        {
            "id": "6411b678201352f04a000036_0001",
            "question": "is prosopagnosia inherited or  acquired?",
            "type": "factoid",
            "context": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired form of prosopagnosia we studied the congenital form"
        },
        {
            "id": "6411b678201352f04a000036_0002",
            "question": "is prosopagnosia inherited or  acquired?",
            "type": "factoid",
            "context": "Congenital prosopagnosia (cPA) is a selective impairment in the visual learning and recognition of faces without detectable brain damage or malformation. There is evidence that it can be inherited in an autosomal dominant mode of inheritance."
        },
        {
            "id": "6411b678201352f04a000036_0003",
            "question": "is prosopagnosia inherited or  acquired?",
            "type": "factoid",
            "context": "Here we report a follow-up examination on multiple sclerosi.T., suffering from acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal, "
        },
        {
            "id": "643bc8f957b1c7a31500002b_0001",
            "question": "Where are promoters typically found in DNA?",
            "type": "factoid",
            "context": "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site. "
        },
        {
            "id": "643bc8f957b1c7a31500002b_0002",
            "question": "Where are promoters typically found in DNA?",
            "type": "factoid",
            "context": "Promoters mark the start of every transcript and are an important class of regulatory elements."
        },
        {
            "id": "64403be357b1c7a31500004e_0001",
            "question": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?",
            "type": "factoid",
            "context": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression."
        },
        {
            "id": "644289c457b1c7a31500005e_0001",
            "question": "Which are some symptoms of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles."
        },
        {
            "id": "644289c457b1c7a31500005e_0002",
            "question": "Which are some symptoms of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "Weakness is progressive and frequently asymmetric, which is a hallmark of the disease."
        },
        {
            "id": "644289c457b1c7a31500005e_0003",
            "question": "Which are some symptoms of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "5 major Facioscapulohumeral Muscular Dystrophy symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss."
        },
        {
            "id": "6440396957b1c7a31500004b_0001",
            "question": "What is the mode of delivery of the drug XIPERE?",
            "type": "factoid",
            "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 Food and Drug Administration approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal (Schlemm's canal) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions, thereby potentially addressing some of the efficacy, safety, and treatment burden limitations of current retinal therapies. "
        },
        {
            "id": "6440396957b1c7a31500004b_0002",
            "question": "What is the mode of delivery of the drug XIPERE?",
            "type": "factoid",
            "context": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions."
        },
        {
            "id": "641791ca690f196b51000031_0001",
            "question": "What are the most common muscular dystrophies?",
            "type": "list",
            "context": " Congenital muscular dystrophies (Congenital muscular dystrophies) include dystroglycanopathies, merosin-deficient Congenital muscular dystrophies, collagen VI-deficient Congenital muscular dystrophies, SELENON-related rigid spine muscular dystrophy, and LMNA-related Congenital muscular dystrophies."
        },
        {
            "id": "641791ca690f196b51000031_0002",
            "question": "What are the most common muscular dystrophies?",
            "type": "list",
            "context": "Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy."
        },
        {
            "id": "6431708a57b1c7a315000017_0001",
            "question": "Where does Brain (or B type) Natriuretic Protein, brain natriuretic peptide usually originate from?",
            "type": "factoid",
            "context": "We explored the direct impact of T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (natriuretic peptide) expression. A"
        },
        {
            "id": "6431708a57b1c7a315000017_0002",
            "question": "Where does Brain (or B type) Natriuretic Protein, brain natriuretic peptide usually originate from?",
            "type": "factoid",
            "context": "In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145, the relative messenger ribonucleic acid (messenger ribonucleic acid) and protein expressions of atrial natriuretic peptide (atrial natriuretic peptide) and B-type natriuretic peptide (brain natriuretic peptide) induced by PE decreased."
        },
        {
            "id": "6431708a57b1c7a315000017_0003",
            "question": "Where does Brain (or B type) Natriuretic Protein, brain natriuretic peptide usually originate from?",
            "type": "factoid",
            "context": "Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (brain natriuretic peptide). Intracellular calcium-elevating agents such as the calcium ionophore A23187,"
        },
        {
            "id": "644291fa57b1c7a31500005f_0001",
            "question": "Which are the types of myotonic dystrophy?",
            "type": "list",
            "context": "DM type 2 (DM2) is considered less severe than DM type 1 (DM1), but it is unknown whether this applies uniformly to all features. "
        },
        {
            "id": "63f741a633942b094c000009_0001",
            "question": "What are the active components of Opdualag?",
            "type": "list",
            "context": "Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (Food and Drug Administration) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. "
        },
        {
            "id": "63f741a633942b094c000009_0002",
            "question": "What are the active components of Opdualag?",
            "type": "list",
            "context": "Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag\u2122) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers."
        },
        {
            "id": "63f741a633942b094c000009_0003",
            "question": "What are the active components of Opdualag?",
            "type": "list",
            "context": "DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications."
        },
        {
            "id": "640f8641201352f04a00002c_0001",
            "question": "Where in the body would  Schlemm's canal be found",
            "type": "factoid",
            "context": " This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of Schlemm's canal in a single procedure"
        },
        {
            "id": "640f8641201352f04a00002c_0002",
            "question": "Where in the body would  Schlemm's canal be found",
            "type": "factoid",
            "context": "To study the effect of 3 Schlemm's canal (Schlemm's canal) microinvasive glaucoma surgery (microinvasive glaucoma surgery) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P"
        },
        {
            "id": "640f8641201352f04a00002c_0003",
            "question": "Where in the body would  Schlemm's canal be found",
            "type": "factoid",
            "context": "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices."
        },
        {
            "id": "640f8641201352f04a00002c_0004",
            "question": "Where in the body would  Schlemm's canal be found",
            "type": "factoid",
            "context": "Previously, blood reflux from Schlemm's canal (Schlemm's canal) after long-standing glaucoma surgery was reported in eyes treated with excisional LOT"
        },
        {
            "id": "640f8641201352f04a00002c_0005",
            "question": "Where in the body would  Schlemm's canal be found",
            "type": "factoid",
            "context": "AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma "
        },
        {
            "id": "644009c557b1c7a315000041_0001",
            "question": "What is the mode of inheritance of Friedreich\u2019s ataxia?",
            "type": "factoid",
            "context": "Friedreich's Ataxia (Friedreich's ataxia) is an autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (dorsal root ganglia), cerebellar dentate nuclei and heart. "
        },
        {
            "id": "64371a4257b1c7a315000029_0001",
            "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
            "type": "factoid",
            "context": "Coordinated gene expression allows spatiotemporal control of cellular processes and is achieved by the cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway."
        },
        {
            "id": "64371a4257b1c7a315000029_0002",
            "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
            "type": "factoid",
            "context": "The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription."
        },
        {
            "id": "64371a4257b1c7a315000029_0003",
            "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
            "type": "factoid",
            "context": "Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes."
        },
        {
            "id": "6440377c57b1c7a315000049_0001",
            "question": "What is the active ingredient of Xipere?",
            "type": "factoid",
            "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 Food and Drug Administration approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. "
        },
        {
            "id": "64163568690f196b5100001b_0001",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Distal hotspot exons 47, 48 and 50 were the commonly deleted exons."
        },
        {
            "id": "64163568690f196b5100001b_0002",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients"
        },
        {
            "id": "64163568690f196b5100001b_0003",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "We confirmed that del45-55 segregates a high proportion of benign phenotypes, severe cases, and isolated cardiac and cognitive presentations."
        },
        {
            "id": "64163568690f196b5100001b_0004",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "In particular, exons 45-52 constitute a hotspot for DMD mutations. "
        },
        {
            "id": "64163568690f196b5100001b_0005",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%)."
        },
        {
            "id": "64163568690f196b5100001b_0006",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "In-frame exon skipping of dystrophin exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this \"hotspot\" region."
        },
        {
            "id": "64163568690f196b5100001b_0007",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Here, we provide an update on DMD genotype-phenotype associations using a global DMD database and further provide the rationale for multiple exon skipping development, particularly for exons 45\u207b55 skipping and an emerging therapeutic concept, exons 3\u207b9 skipping."
        },
        {
            "id": "64163568690f196b5100001b_0008",
            "question": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
            "type": "list",
            "context": " A deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene was detected, and dystrophin protein expression was \u223c15% that of control level."
        },
        {
            "id": "6441057657b1c7a315000052_0001",
            "question": "What is the most commonly used pain scale for the measurement of pain in children?",
            "type": "factoid",
            "context": " Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed."
        },
        {
            "id": "6441057657b1c7a315000052_0002",
            "question": "What is the most commonly used pain scale for the measurement of pain in children?",
            "type": "factoid",
            "context": "The FLACC and COMFORT scales were utilized to assess pain"
        },
        {
            "id": "6441057657b1c7a315000052_0003",
            "question": "What is the most commonly used pain scale for the measurement of pain in children?",
            "type": "factoid",
            "context": "Postoperative pain was assessed using the Visual Analogue Scale (Visual Analogue Scale), the Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. "
        },
        {
            "id": "6441057657b1c7a315000052_0004",
            "question": "What is the most commonly used pain scale for the measurement of pain in children?",
            "type": "factoid",
            "context": "The pain experience (intense, moderate, or mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r)."
        },
        {
            "id": "6441057657b1c7a315000052_0005",
            "question": "What is the most commonly used pain scale for the measurement of pain in children?",
            "type": "factoid",
            "context": " Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively."
        },
        {
            "id": "64257c9c690f196b5100004b_0001",
            "question": "What is drug-induced liver injury causality assessment tool used for?",
            "type": "factoid",
            "context": "We utilised a novel DILI causality assessment tool (drug-induced liver injury causality assessment tool), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development."
        },
        {
            "id": "64257c9c690f196b5100004b_0002",
            "question": "What is drug-induced liver injury causality assessment tool used for?",
            "type": "factoid",
            "context": "A novel phenotype-based drug-induced liver injury causality assessment tool (drug-induced liver injury causality assessment tool) allows for signal confirmation in early drug development."
        },
        {
            "id": "64257c9c690f196b5100004b_0003",
            "question": "What is drug-induced liver injury causality assessment tool used for?",
            "type": "factoid",
            "context": "drug-induced liver injury causality assessment tool, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development."
        },
        {
            "id": "6442869857b1c7a31500005d_0001",
            "question": "Which diagnostic tests are used for the diagnosis of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "In most cases, once Facioscapulohumeral Muscular Dystrophy is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. "
        },
        {
            "id": "6442869857b1c7a31500005d_0002",
            "question": "Which diagnostic tests are used for the diagnosis of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis."
        },
        {
            "id": "6442869857b1c7a31500005d_0003",
            "question": "Which diagnostic tests are used for the diagnosis of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus."
        },
        {
            "id": "6442869857b1c7a31500005d_0004",
            "question": "Which diagnostic tests are used for the diagnosis of Facioscapulohumeral Muscular Dystrophy?",
            "type": "list",
            "context": "We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test."
        },
        {
            "id": "6429e85e57b1c7a315000009_0001",
            "question": "What process involves metabolite-sensing mRNAs to control gene expression?",
            "type": "factoid",
            "context": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control."
        },
        {
            "id": "6429e85e57b1c7a315000009_0002",
            "question": "What process involves metabolite-sensing mRNAs to control gene expression?",
            "type": "factoid",
            "context": "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of messenger ribonucleic acid, where they selectively bind their target compound and subsequently modulate gene expression. We have identified messenger ribonucleic acid elements in fungi and in plants that match the consensus sequence and structure of thiamine pyrophosphate-binding domains of prokaryotes."
        },
        {
            "id": "6429e85e57b1c7a315000009_0003",
            "question": "What process involves metabolite-sensing mRNAs to control gene expression?",
            "type": "factoid",
            "context": "Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements."
        },
        {
            "id": "6429e85e57b1c7a315000009_0004",
            "question": "What process involves metabolite-sensing mRNAs to control gene expression?",
            "type": "factoid",
            "context": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression. The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts."
        },
        {
            "id": "641794e7690f196b51000036_0001",
            "question": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
            "type": "list",
            "context": " In DMD, there was a prevalence of 7.0% of autism spectrum disorders, 18.0% of attention-deficit hyperactivity disorder, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of obsessive-compulsive disorder."
        },
        {
            "id": "641794e7690f196b51000036_0002",
            "question": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
            "type": "list",
            "context": "To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (autism spectrum disorders), attention-deficit hyperactivity disorder (attention-deficit hyperactivity disorder), depression, anxiety disorders, and obsessive-compulsive disorder (obsessive-compulsive disorder), in populations with Duchenne muscular dystrophy (DMD)"
        },
        {
            "id": "641794e7690f196b51000036_0003",
            "question": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (autism spectrum disorder)"
        },
        {
            "id": "641794e7690f196b51000036_0004",
            "question": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. "
        },
        {
            "id": "63ee5c78f36125a426000001_0001",
            "question": "Which interleukins are affected by Dupilumab?",
            "type": "list",
            "context": "Dupilumab, a monoclonal antibody targeting the interleukin (interleukin)-4 receptor alpha to inhibit interleukin-4 and interleukin-13 signaling, has recently been shown to significantly improve the condition of patients with CRSwNP."
        },
        {
            "id": "63ee5c78f36125a426000001_0002",
            "question": "Which interleukins are affected by Dupilumab?",
            "type": "list",
            "context": "BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor \u03b1, used in the treatment of atopic dermatitis (atopic dermatitis)."
        },
        {
            "id": "63ee5c78f36125a426000001_0003",
            "question": "Which interleukins are affected by Dupilumab?",
            "type": "list",
            "context": "The development of new therapies received great impetus by an ample research of the pathophysiological mechanisms, leading to a new era in the treatment of severe atopic eczema due to targeted treatments, e.g. the interleukin-4R alpha specific monoclonal antibody dupilumab."
        },
        {
            "id": "63ee5c78f36125a426000001_0004",
            "question": "Which interleukins are affected by Dupilumab?",
            "type": "list",
            "context": "BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (interleukin)-4 andIL-13, key and central drivers of type 2 inflammation. "
        },
        {
            "id": "63ee5c78f36125a426000001_0005",
            "question": "Which interleukins are affected by Dupilumab?",
            "type": "list",
            "context": " An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-R\u03b1) and the signaling pathways activated by interleukin (interleukin)-4 and interleukin-13. "
        },
        {
            "id": "64316f8e57b1c7a315000016_0001",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": " Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors"
        },
        {
            "id": "64316f8e57b1c7a315000016_0002",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": " Autologous cartilage regeneration is a cell-based therapy in which autogenous chondrocytes or other chondrogenic cells are cultured to constitute cartilaginous tissue according to the principles of tissue engineering."
        },
        {
            "id": "64316f8e57b1c7a315000016_0003",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "Cartilage engineered from chondrocytes requires a scaffold to keep the cells in the cartilage defect and to act as a support for inducing hyaline cartilage formation "
        },
        {
            "id": "64316f8e57b1c7a315000016_0004",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "To address these challenges, the focus of gene therapy for bone and cartilage repair has shifted in recent years to the use of autologous cells, typically osteocytes or chondrocytes, or their progenitors, "
        },
        {
            "id": "64316f8e57b1c7a315000016_0005",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "Articular Cartilage Chondrocytes are more Advantageous for Generating Hyaline-like Cartilage than Mesenchymal Cells Isolated from Microfracture Repairs"
        },
        {
            "id": "64316f8e57b1c7a315000016_0006",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks."
        },
        {
            "id": "64316f8e57b1c7a315000016_0007",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "affect neocartilage formation by encapsulated auricular chondrocytes."
        },
        {
            "id": "64316f8e57b1c7a315000016_0008",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "Transplanting human umbilical cord mesenchymal stem cells and hyaluronate hydrogel repairs cartilage of osteoarthritis in the minipig model."
        },
        {
            "id": "64316f8e57b1c7a315000016_0009",
            "question": "What cells are used to regenerate cartilage?",
            "type": "list",
            "context": "Osteoarthritis (Osteoarthritis) is a chronic disease of degenerative joints. Mesenchymal stem cells (Mesenchymal stem cells) have been used for cartilage regeneration in Osteoarthritis. "
        },
        {
            "id": "6440393157b1c7a31500004a_0001",
            "question": "Which year was XIPERE approved by the Food and Drug Administration?",
            "type": "factoid",
            "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 Food and Drug Administration approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. "
        },
        {
            "id": "6415b3b4690f196b51000009_0001",
            "question": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?",
            "type": "factoid",
            "context": "Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light."
        },
        {
            "id": "6429fad757b1c7a31500000e_0001",
            "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
            "type": "factoid",
            "context": "A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site."
        },
        {
            "id": "6429fad757b1c7a31500000e_0002",
            "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
            "type": "factoid",
            "context": "About 24% of human genes have a TATA-like element and their promoters are generally AT-rich; however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR)."
        },
        {
            "id": "6429fad757b1c7a31500000e_0003",
            "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
            "type": "factoid",
            "context": "TATA-binding protein binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin."
        },
        {
            "id": "6429fad757b1c7a31500000e_0004",
            "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
            "type": "factoid",
            "context": "The TATA-binding protein (TATA-binding protein) is one of the major components of the human TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box) found in many eukaryotic promoters. "
        },
        {
            "id": "64402e7757b1c7a315000044_0001",
            "question": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
            "type": "factoid",
            "context": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort)"
        },
        {
            "id": "64402e7757b1c7a315000044_0002",
            "question": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
            "type": "factoid",
            "context": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements."
        },
        {
            "id": "64425ce357b1c7a315000059_0001",
            "question": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?",
            "type": "factoid",
            "context": "Facioscapulohumeral Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy) is in the top three list of all dystrophies with an approximate 1:8000 incidence."
        },
        {
            "id": "64425ce357b1c7a315000059_0002",
            "question": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?",
            "type": "factoid",
            "context": "It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly."
        },
        {
            "id": "63f581e933942b094c000007_0001",
            "question": "Risdiplam is used for treatment of which disease?",
            "type": "factoid",
            "context": "Risdiplam (Evrysdi)-an orally bioavailable, small molecule approved by the US Food and Drug Administration and more recently by the European Medicines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study."
        },
        {
            "id": "63f581e933942b094c000007_0002",
            "question": "Risdiplam is used for treatment of which disease?",
            "type": "factoid",
            "context": "An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy."
        },
        {
            "id": "63f581e933942b094c000007_0003",
            "question": "Risdiplam is used for treatment of which disease?",
            "type": "factoid",
            "context": "OBJECTIVE: The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (spinal muscular atrophy) who had no satisfactory treatment options access to risdiplam prior to commercial availability. "
        },
        {
            "id": "63f581e933942b094c000007_0004",
            "question": "Risdiplam is used for treatment of which disease?",
            "type": "factoid",
            "context": "SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons. Major advances and developments in spinal muscular atrophy therapeutics are shifting the natural history of the disease. With three relatively new available therapies, nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi), patients survive longer and have improved outcomes. "
        },
        {
            "id": "641c5201690f196b51000040_0001",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "To evaluate the predictive value of serum neurofilament light chain (Serum neurofilament light) and cerebrospinal fluid Neurofilament light chain (cerebrospinal fluid Neurofilament light chain) in patients with radiologically isolated syndrome (radiologically isolated syndrome) for evidence of disease activity (evidence of disease activity) and clinical conversion (clinical conversion)"
        },
        {
            "id": "641c5201690f196b51000040_0002",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome."
        },
        {
            "id": "641c5201690f196b51000040_0003",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "eurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (multiple sclerosis) and can be quantified by serum neurofilament light chain (Serum neurofilament light) and glial fibrillary acidic protein (sGFAP"
        },
        {
            "id": "641c5201690f196b51000040_0004",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Serum glial fibrillary acidic protein and Neurofilament light chain Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis."
        },
        {
            "id": "641c5201690f196b51000040_0005",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Serum neurofilament light reflected acute disease activity in patients with multiple sclerosis at high risk of underlying progressive pathology"
        },
        {
            "id": "641c5201690f196b51000040_0006",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Thus, sGFAP and Serum neurofilament light levels may be used to stratify patients with progressive multiple sclerosis for clinical research studies and clinical trials and may inform clinical care."
        },
        {
            "id": "641c5201690f196b51000040_0007",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease."
        },
        {
            "id": "641c5201690f196b51000040_0008",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Neurofilament light-chain (Neurofilament light chain) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma Neurofilament light chain levels in children with chronic kidney disease (chronic kidney disease) and healthy peers, (2) characterize the relationship between Neurofilament light chain level and kidney function, and (3) evaluate Neurofilament light chain as a predictor of abnormal brain structure in chronic kidney disease"
        },
        {
            "id": "641c5201690f196b51000040_0009",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Within the chronic kidney disease sample, Neurofilament light chain level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric chronic kidney disease."
        },
        {
            "id": "641c5201690f196b51000040_0010",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (Neurofilament light chain), glial fibrillary acidic protein (glial fibrillary acidic protein), and glial fibrillary acidic protein/Neurofilament light chain levels.R"
        },
        {
            "id": "641c5201690f196b51000040_0011",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases."
        },
        {
            "id": "641c5201690f196b51000040_0012",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "erum Neurofilament light chain and glial fibrillary acidic protein could be potential diagnostic biomarkers for BM in patients with lung cancer. We established a model that can provide individual diagnoses of BM. Higher Neurofilament light chain level may be associated with poor prognosis of patients with BM."
        },
        {
            "id": "641c5201690f196b51000040_0013",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": " The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (Neurofilament light chain) and phosphorylated neurofilaments heavy chain (phosphorylated neurofilaments heavy chain) in a context of FAS."
        },
        {
            "id": "641c5201690f196b51000040_0014",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Comparative diagnosis interest of Neurofilament light chain and phosphorylated neurofilaments heavy chain in cerebrospinal fluid and plasma in a context of FTD-ALS spectrum"
        },
        {
            "id": "641c5201690f196b51000040_0015",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia."
        },
        {
            "id": "641c5201690f196b51000040_0016",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Neurofilament light chain is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age."
        },
        {
            "id": "641c5201690f196b51000040_0017",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": " The neurofilament light chain (Neurofilament light chain) has emerged as a versatile biomarker for CNS-diseases and is approaching clinical use."
        },
        {
            "id": "641c5201690f196b51000040_0018",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": ": Serum neurofilament light (Serum neurofilament light) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (multiple sclerosis)."
        },
        {
            "id": "641c5201690f196b51000040_0019",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis."
        },
        {
            "id": "641c5201690f196b51000040_0020",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Serum Neurofilament light chain concentration was the only factor associated with disease worsening, indicating that Serum neurofilament light is a useful biomarker in multiple sclerosis that might be relevant in a clinical setting."
        },
        {
            "id": "641c5201690f196b51000040_0021",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Patients with Langerhans cell histiocytosis (Langerhans cell histiocytosis) may develop progressive neurodegeneration in the central nervous system (ND-CNS-Langerhans cell histiocytosis). Neurofilament light protein (Neurofilament light protein) in cerebrospinal fluid (cerebrospinal fluid) is a promising biomarker to detect and monitor ND-CNS-Langerhans cell histiocytosis."
        },
        {
            "id": "641c5201690f196b51000040_0022",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma."
        },
        {
            "id": "641c5201690f196b51000040_0023",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Thus, our results suggest that p-Neurofilament light protein may be used to screen for ND-CNS-Langerhans cell histiocytosis. Further studies are encouraged, including the role of p-Neurofilament light protein for monitoring of ND-CNS-Langerhans cell histiocytosis."
        },
        {
            "id": "641c5201690f196b51000040_0024",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Elevated serum Neurofilament Light chain (Neurofilament light chain) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1)."
        },
        {
            "id": "641c5201690f196b51000040_0025",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Circulating Neurofilament light chain (Neurofilament light chain) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders."
        },
        {
            "id": "641c5201690f196b51000040_0026",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies."
        },
        {
            "id": "641c5201690f196b51000040_0027",
            "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (Neurofilament light chain).",
            "type": "list",
            "context": "To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies."
        },
        {
            "id": "643c183b57b1c7a31500002c_0001",
            "question": "What are the most common assays to profile chromatin accessibility?",
            "type": "list",
            "context": "Accessible chromatin often represents gene regulatory elements, including promoters and enhancers, essential for gene expression. Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) is one of the most popular techniques to investigate chromatin accessibility across the genome."
        },
        {
            "id": "643c183b57b1c7a31500002c_0002",
            "question": "What are the most common assays to profile chromatin accessibility?",
            "type": "list",
            "context": "Functional cis-regulatory elements (cis-regulatory elements) act as precise transcriptional switches for fine-tuning gene transcription. Identification of cis-regulatory elements is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes. It is well known that cis-regulatory elements reside in open chromatin that exhibits hypersensitivity to enzyme cleavage and physical shearing. Currently, high-throughput methodologies, such as DNase-seq, ATAC-seq, and FAIRE-seq, have been widely applied in mapping open chromatin in various eukaryotic genomes. More recently, differential MNase (micrococcal nuclease) treatment has been successfully employed to map open chromatin in addition to profiling nucleosome landscape in both mammalian and plant species."
        },
        {
            "id": "643c183b57b1c7a31500002c_0003",
            "question": "What are the most common assays to profile chromatin accessibility?",
            "type": "list",
            "context": "Micrococcal nuclease (MNase) originating from Staphylococcus aureus is a calcium dependent ribo- and desoxyribonuclease which has endo- and exonucleolytic activity of low sequence preference. MNase is widely used to analyze nucleosome positions in chromatin by probing the enzyme's DNA accessibility in limited digestion reactions."
        },
        {
            "id": "643c183b57b1c7a31500002c_0004",
            "question": "What are the most common assays to profile chromatin accessibility?",
            "type": "list",
            "context": "In this review, we discuss techniques for determining DNA accessibility and nucleosome positioning (DNase-seq, FAIRE-seq, MNase-seq, and ATAC-seq) and techniques for detecting and functionally characterizing chromatin-bound proteins (ChIP-seq, DamID, and CUT&RUN)."
        },
        {
            "id": "643c183b57b1c7a31500002c_0005",
            "question": "What are the most common assays to profile chromatin accessibility?",
            "type": "list",
            "context": "Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine DNA accessibility and protein localization on chromatin genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression; conversely, genomic regions that are highly occupied by histone proteins are not permissive for factor binding and are less likely to be active regulatory regions."
        },
        {
            "id": "64402f6f57b1c7a315000045_0001",
            "question": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?",
            "type": "list",
            "context": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days."
        },
        {
            "id": "6440f85c57b1c7a315000051_0001",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "The tools used to control pain in infants in the article included Pain Profile,Neonatal Facial Coding System,Neonatal Infant Pain Scale AND NPASS. "
        },
        {
            "id": "6440f85c57b1c7a315000051_0002",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "The Neonatal Pain, Agitation, and Sedation Scale (Neonatal Pain, Agitation, and Sedation Scale) and the Neonatal Infant Pain Scale (Neonatal Infant Pain Scale) are valid measures of pain. "
        },
        {
            "id": "6440f85c57b1c7a315000051_0003",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "Fifteen bedside nurses trained to use the Neonatal Pain, Agitation, and Sedation Scale and the Neonatal Infant Pain Scale prospectively completed 202 pain/agitation and sedation assessments from a convenience sample of 88 infants, including chronically ventilated, medically fragile infants. "
        },
        {
            "id": "6440f85c57b1c7a315000051_0004",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "The present study evaluated the correlation of Neonatal Infant Pain Scale (Neonatal Infant Pain Scale) and Premature Infant Pain Profile-Revised (Pain Profile-Revised), with changes in cerebral oxygenation (\u0394crSO2; measured by near-infrared spectroscopy) in preterm infants during acute painful procedures (heel lance and venepuncture)."
        },
        {
            "id": "6440f85c57b1c7a315000051_0005",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "A cornerstone in pain assessment is the use of scales such as COMFORT, Pain Profile-Revised, Neonatal Infant Pain Scale and Neonatal Pain, Agitation, and Sedation Scale. "
        },
        {
            "id": "6440f85c57b1c7a315000051_0006",
            "question": "What are the most common pain scales used to measure pain in neonates?",
            "type": "list",
            "context": "The aim of this study was to assess the reliability, validity, and clinical utility of the Neonatal Facial Coding System (Neonatal Facial Coding System), Douleur Aigu\u00eb du Nouveau-n\u00e9 (DAN) scale, Neonatal Infant Pain Scale (Neonatal Infant Pain Scale), and Premature Infant Pain Profile (Pain Profile) in premature infants undergoing heel blood collection."
        },
        {
            "id": "6431f7de57b1c7a31500001b_0001",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "Friedreich's ataxia (Friedreich's ataxia) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (guanine-adenine-adenine) triplet expansion in the frataxin (frataxin) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1. "
        },
        {
            "id": "6431f7de57b1c7a31500001b_0002",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "Friedreich's ataxia (Friedreich's ataxia) is an inherited, multisystemic disorder predominantly caused by guanine-adenine-adenine hyper expansion in intron 1 of frataxin (frataxin) gene. "
        },
        {
            "id": "6431f7de57b1c7a31500001b_0003",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin."
        },
        {
            "id": "6431f7de57b1c7a31500001b_0004",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood."
        },
        {
            "id": "6431f7de57b1c7a31500001b_0005",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and Friedreich's ataxia patients. "
        },
        {
            "id": "6431f7de57b1c7a31500001b_0006",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "The mean levels of mature frataxin in whole blood from healthy controls and homozygous Friedreich's ataxia patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively. "
        },
        {
            "id": "6431f7de57b1c7a31500001b_0007",
            "question": "What gene is mutated in Friedreich's ataxia?",
            "type": "factoid",
            "context": "he mean levels of total frataxin in whole blood from healthy controls and homozygous Friedreich's ataxia patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3 ng/mL and 6.8 \u00b1 4.0 ng/mL, respectively. "
        },
        {
            "id": "643f9eeb57b1c7a31500003c_0001",
            "question": "What is the incidence of Duchenne Muscular Dystrophy?",
            "type": "factoid",
            "context": "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births."
        },
        {
            "id": "643f9eeb57b1c7a31500003c_0002",
            "question": "What is the incidence of Duchenne Muscular Dystrophy?",
            "type": "factoid",
            "context": "The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD."
        },
        {
            "id": "6402ba49201352f04a000004_0001",
            "question": "Which drugs were studied in the TRICOTEL study?",
            "type": "list",
            "context": "Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study."
        },
        {
            "id": "6402ba49201352f04a000004_0002",
            "question": "Which drugs were studied in the TRICOTEL study?",
            "type": "list",
            "context": "METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). "
        },
        {
            "id": "6415c252690f196b51000011_0001",
            "question": "Which cancer is the bacillus Calmette-Guerin vaccine used for?",
            "type": "factoid",
            "context": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status."
        },
        {
            "id": "6415c252690f196b51000011_0002",
            "question": "Which cancer is the bacillus Calmette-Guerin vaccine used for?",
            "type": "factoid",
            "context": "In the past decades, the bacillus Calmette-Guerin (bacillus Calmette-Guerin) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical bacillus Calmette-Guerin instillation."
        },
        {
            "id": "641791b9690f196b51000030_0001",
            "question": "What are the most common congenital muscular dystrophies?",
            "type": "list",
            "context": "Congenital muscular dystrophies (Congenital muscular dystrophies) include dystroglycanopathies, merosin-deficient Congenital muscular dystrophies, collagen VI-deficient Congenital muscular dystrophies, SELENON-related rigid spine muscular dystrophy, and LMNA-related Congenital muscular dystrophies."
        },
        {
            "id": "63eeed0af36125a426000007_0001",
            "question": "What disease can be treated with Teclistamab?",
            "type": "factoid",
            "context": "Teclistamab in Relapsed or Refractory Multiple Myeloma."
        },
        {
            "id": "63eeed0af36125a426000007_0002",
            "question": "What disease can be treated with Teclistamab?",
            "type": "factoid",
            "context": "In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma."
        },
        {
            "id": "63eeed0af36125a426000007_0003",
            "question": "What disease can be treated with Teclistamab?",
            "type": "factoid",
            "context": "CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma."
        },
        {
            "id": "63eeed0af36125a426000007_0004",
            "question": "What disease can be treated with Teclistamab?",
            "type": "factoid",
            "context": "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma."
        },
        {
            "id": "63eeed0af36125a426000007_0005",
            "question": "What disease can be treated with Teclistamab?",
            "type": "factoid",
            "context": "BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies."
        },
        {
            "id": "643d3e6157b1c7a315000034_0001",
            "question": "Please list the natriuretic peptides.",
            "type": "list",
            "context": "Nonlinear laser wave-mixing spectroscopy is demonstrated as a fast and sensitive detection method for heart-failure biomarkers, pro-atrial natriuretic peptide (proANP) and brain natriuretic peptide (brain natriuretic peptide). "
        },
        {
            "id": "643d3e6157b1c7a315000034_0002",
            "question": "Please list the natriuretic peptides.",
            "type": "list",
            "context": "Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated cardiac-filling pressures or clinical heart failure. Elevation of brain natriuretic peptide (brain natriuretic peptide) or NT-proBNP is associated with worse outcomes among patients with Acute Respiratory Distress Syndrome (ARDS)."
        },
        {
            "id": "643d3e6157b1c7a315000034_0003",
            "question": "Please list the natriuretic peptides.",
            "type": "list",
            "context": "Natriuretic peptides (NPs, B-type natriuretic peptide /brain natriuretic peptide and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (heart failure)."
        },
        {
            "id": "63f03ea0f36125a426000020_0001",
            "question": "SER-109 is developed for prevention of which disease?",
            "type": "factoid",
            "context": "In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. "
        },
        {
            "id": "63f03ea0f36125a426000020_0002",
            "question": "SER-109 is developed for prevention of which disease?",
            "type": "factoid",
            "context": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection."
        },
        {
            "id": "63f03ea0f36125a426000020_0003",
            "question": "SER-109 is developed for prevention of which disease?",
            "type": "factoid",
            "context": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection."
        },
        {
            "id": "63f03ea0f36125a426000020_0004",
            "question": "SER-109 is developed for prevention of which disease?",
            "type": "factoid",
            "context": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2."
        },
        {
            "id": "64179113690f196b5100002e_0001",
            "question": "Where is the DMD gene located?",
            "type": "factoid",
            "context": "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus."
        },
        {
            "id": "64179113690f196b5100002e_0002",
            "question": "Where is the DMD gene located?",
            "type": "factoid",
            "context": "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (Becker muscular dystrophy) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21."
        },
        {
            "id": "64179113690f196b5100002e_0003",
            "question": "Where is the DMD gene located?",
            "type": "factoid",
            "context": "The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). "
        },
        {
            "id": "6415c9e9690f196b51000018_0001",
            "question": "Which form of breast cancer has Keytruda been Food and Drug Administration approved for?",
            "type": "factoid",
            "context": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC, as the Food and Drug Administration recently approved atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in combination with chemotherapy. "
        }
    ]
}